Cargando…
From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus
Virtual screening, a fast, computational approach to identify drug leads [Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G. J. Med. Chem.2000, 43, 401; Miller, M. A. Nat. Rev. Drug Disc.2002, 1 220], is limited by a known challenge in crystallographically determining flexible...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119130/ https://www.ncbi.nlm.nih.gov/pubmed/16325400 http://dx.doi.org/10.1016/j.bmcl.2005.11.018 |
_version_ | 1783514713551798272 |
---|---|
author | Dooley, Andrea J. Shindo, Nice Taggart, Barbara Park, Jewn-Giew Pang, Yuan-Ping |
author_facet | Dooley, Andrea J. Shindo, Nice Taggart, Barbara Park, Jewn-Giew Pang, Yuan-Ping |
author_sort | Dooley, Andrea J. |
collection | PubMed |
description | Virtual screening, a fast, computational approach to identify drug leads [Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G. J. Med. Chem.2000, 43, 401; Miller, M. A. Nat. Rev. Drug Disc.2002, 1 220], is limited by a known challenge in crystallographically determining flexible regions of proteins. This approach has not been able to identify active inhibitors of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) using solely the crystal structures of a SARS-CoV cysteine proteinase with a flexible loop in the active site [Yang, H. T.; Yang, M. J.; Ding, Y.; Liu, Y. W.; Lou, Z. Y. Proc. Natl. Acad. Sci. U.S.A.2003, 100, 13190; Jenwitheesuk, E.; Samudrala, R. Bioorg. Med. Chem. Lett.2003, 13, 3989; Rajnarayanan, R. V.; Dakshanamurthy, S.; Pattabiraman, N. Biochem. Biophys. Res. Commun.2004, 321, 370; Du, Q.; Wang, S.; Wei, D.; Sirois, S.; Chou, K. Anal. Biochem.2005, 337, 262; Du, Q.; Wang, S.; Zhu, Y.; Wei, D.; Guo, H. Peptides2004, 25, 1857; Lee, V.; Wittayanarakul, K.; Remsungenen, T.; Parasuk, V.; Sompornpisut, P. Science (Asia)2003, 29, 181; Toney, J.; Navas-Martin, S.; Weiss, S.; Koeller, A. J. Med. Chem.2004, 47, 1079; Zhang, X. W.; Yap, Y. L. Bioorg. Med. Chem.2004, 12, 2517]. This article demonstrates a genome-to-drug-lead approach that uses terascale computing to model flexible regions of proteins, thus permitting the utilization of genetic information to identify drug leads expeditiously. A small-molecule inhibitor of SARS-CoV, exhibiting an effective concentration (EC(50)) of 23 μM in cell-based assays, was identified through virtual screening against a computer-predicted model of the cysteine proteinase. Screening against two crystal structures of the same proteinase failed to identify the 23-μM inhibitor. This study suggests that terascale computing can complement crystallography, broaden the scope of virtual screening, and accelerate the development of therapeutics to treat emerging infectious diseases such as SARS and Bird Flu. |
format | Online Article Text |
id | pubmed-7119130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71191302020-04-03 From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus Dooley, Andrea J. Shindo, Nice Taggart, Barbara Park, Jewn-Giew Pang, Yuan-Ping Bioorg Med Chem Lett Article Virtual screening, a fast, computational approach to identify drug leads [Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G. J. Med. Chem.2000, 43, 401; Miller, M. A. Nat. Rev. Drug Disc.2002, 1 220], is limited by a known challenge in crystallographically determining flexible regions of proteins. This approach has not been able to identify active inhibitors of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) using solely the crystal structures of a SARS-CoV cysteine proteinase with a flexible loop in the active site [Yang, H. T.; Yang, M. J.; Ding, Y.; Liu, Y. W.; Lou, Z. Y. Proc. Natl. Acad. Sci. U.S.A.2003, 100, 13190; Jenwitheesuk, E.; Samudrala, R. Bioorg. Med. Chem. Lett.2003, 13, 3989; Rajnarayanan, R. V.; Dakshanamurthy, S.; Pattabiraman, N. Biochem. Biophys. Res. Commun.2004, 321, 370; Du, Q.; Wang, S.; Wei, D.; Sirois, S.; Chou, K. Anal. Biochem.2005, 337, 262; Du, Q.; Wang, S.; Zhu, Y.; Wei, D.; Guo, H. Peptides2004, 25, 1857; Lee, V.; Wittayanarakul, K.; Remsungenen, T.; Parasuk, V.; Sompornpisut, P. Science (Asia)2003, 29, 181; Toney, J.; Navas-Martin, S.; Weiss, S.; Koeller, A. J. Med. Chem.2004, 47, 1079; Zhang, X. W.; Yap, Y. L. Bioorg. Med. Chem.2004, 12, 2517]. This article demonstrates a genome-to-drug-lead approach that uses terascale computing to model flexible regions of proteins, thus permitting the utilization of genetic information to identify drug leads expeditiously. A small-molecule inhibitor of SARS-CoV, exhibiting an effective concentration (EC(50)) of 23 μM in cell-based assays, was identified through virtual screening against a computer-predicted model of the cysteine proteinase. Screening against two crystal structures of the same proteinase failed to identify the 23-μM inhibitor. This study suggests that terascale computing can complement crystallography, broaden the scope of virtual screening, and accelerate the development of therapeutics to treat emerging infectious diseases such as SARS and Bird Flu. Elsevier Ltd. 2006-02-15 2005-12-01 /pmc/articles/PMC7119130/ /pubmed/16325400 http://dx.doi.org/10.1016/j.bmcl.2005.11.018 Text en Copyright © 2005 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Dooley, Andrea J. Shindo, Nice Taggart, Barbara Park, Jewn-Giew Pang, Yuan-Ping From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus |
title | From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus |
title_full | From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus |
title_fullStr | From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus |
title_full_unstemmed | From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus |
title_short | From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus |
title_sort | from genome to drug lead: identification of a small-molecule inhibitor of the sars virus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119130/ https://www.ncbi.nlm.nih.gov/pubmed/16325400 http://dx.doi.org/10.1016/j.bmcl.2005.11.018 |
work_keys_str_mv | AT dooleyandreaj fromgenometodrugleadidentificationofasmallmoleculeinhibitorofthesarsvirus AT shindonice fromgenometodrugleadidentificationofasmallmoleculeinhibitorofthesarsvirus AT taggartbarbara fromgenometodrugleadidentificationofasmallmoleculeinhibitorofthesarsvirus AT parkjewngiew fromgenometodrugleadidentificationofasmallmoleculeinhibitorofthesarsvirus AT pangyuanping fromgenometodrugleadidentificationofasmallmoleculeinhibitorofthesarsvirus |